Key result
A 59-year-old female developed Takotsubo cardiomyopathy and cardiogenic shock three days after receiving a Moderna COVID-19 vaccine booster dose, which resolved with medical management.
Why the study?
Although uncommon, adverse cardiovascular effects including takotsubo cardiomyopathy have been reported following COVID-19 vaccination as safety data continue to emerge.
Does the COVID-19 vaccine booster dose trigger Takotsubo cardiomyopathy?
Case Report (n=1)
No
Does the COVID-19 vaccine booster dose trigger Takotsubo cardiomyopathy?
COVID-19 mRNA vaccine booster doses may rarely trigger Takotsubo cardiomyopathy, which clinicians should consider in patients presenting with chest pain and dyspnea post-vaccination.
Alerts clinicians to consider Takotsubo cardiomyopathy after mRNA boosters; leaves open causality and requires larger studies before practice change.
Although the efficacy and safety of the coronavirus disease 2019 (COVID-19) vaccine have been established, side effects and adverse events related to the COVID-19 vaccine are still coming out. COVID-19 vaccine also has the potential to cause acute and long-term cardiovascular effects, which include myocarditis, pericarditis, myopericarditis, myocardial infarction, pulmonary embolism, thrombotic thrombocytopenia, and pulmonary hemorrhage. Although uncommon, takotsubo cardiomyopathy (TCM) has also been reported following COVID-19 vaccination. We report a case of TCM following the COVID-19 vaccine in a 59-year-old female who presented with intermittent chest pain and dyspnea following the COVID-19 vaccine booster dose. She had no identifiable triggers for TCM, no risk factors for cardiovascular disease, and normal cardiac enzyme levels, ruling out other causes of cardiac dysfunction. The diagnosis of TCM was supported by imaging findings and the absence of obstructive or thrombotic lesions on angiography.
No takes yet. Share an insight, caveat, or question.
Reza et al. (2023) conducted a case report in Takotsubo Cardiomyopathy (n=1). Moderna COVID-19 vaccine booster was evaluated. A 59-year-old female developed Takotsubo cardiomyopathy and cardiogenic shock three days after receiving a Moderna COVID-19 vaccine booster dose, which resolved with medical management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: